Humana Inc. Plans Quarterly Dividend of $0.89 (NYSE:HUM)

Humana Inc. (NYSE:HUM) declared a quarterly dividend on Thursday, February 20th, RTT News reports. Shareholders of record on Friday, March 28th will be given a dividend of 0.885 per share by the insurance provider on Friday, April 25th. This represents a $3.54 dividend on an annualized basis and a yield of 1.30%.

Humana has increased its dividend by an average of 8.1% annually over the last three years. Humana has a dividend payout ratio of 24.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Humana to earn $13.13 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 27.0%.

Humana Price Performance

HUM stock opened at $271.87 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a one year low of $213.31 and a one year high of $406.46. The stock has a market cap of $32.74 billion, a PE ratio of 27.32, a P/E/G ratio of 2.00 and a beta of 0.56. The firm has a 50 day simple moving average of $269.78 and a two-hundred day simple moving average of $291.15.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday. Morgan Stanley cut their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Barclays upped their price objective on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Finally, Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.